Table 1.
Characteristics of the study groups.
| characteristic | COPD without Bronchiectasis | COPD with Bronchiectasis |
|---|---|---|
| Subjects, n | 19 | 17 |
| Hospitalized, % | 42 | 65 |
| Age, y | 71 (60–75) | 68 (63–79) |
| Male, % | 84 | 88 |
| BMI, kg/m² | 25 (20–30) | 22 (19–27) |
| Pack-years * | 48 (40–55) | 40 (25–45) |
| FEV1, % pred | 51 (39–58) | 41 (37–52) |
| DLCO, % pred | 47 (40–57) | 44 (26–53) |
| GOLD | ||
| I/II/III/IV, % | 0/53/47/0 | 6/29/65/0 |
| A/B/C/D, % | 21/0/16/63 | 12/17/6/65 |
| Eosinophils, % | 1.4 (0.1–3.1) | 2.3 (0.8–4.6) |
| Eosinophils, μL | 200 (0–300) | 200 (100–350) |
| Total IgE, kU/L | 83 (16–592) | 43 (33–298) |
| mMRC | 2 (1–2) | 2 (1.5–3.5) |
| CAT | 14 (12–20) | 19 (13–24) |
| SGRQ | 41.9 (30.6–53.4) | 54.9 (37.3–66.7) |
| ≥2 exacerbations/y, % | 79 | 71 |
| ICS, % | 89 | 82 |
| Modified Reiff score | NA | 4 (2.5–6.5) |
Data are presented as n, % or median (interquartile range). COPD: chronic obstructive pulmonary disease, y: year, BMI: body mass index, FEV1: forced expiratory volume in 1 s, % pred: percentage predicted, DLCO: diffusion capacity of the lung for carbon monoxide, GOLD: Global initiative for chronic Obstructive Lung Disease stadia, mMRC: modified Medical Research Council breathlessness scale, CAT: COPD Assessment Test, SGRQ: Saint Georges Respiratory Questionnaire, ICS: inhaled corticosteroids. * p-value < 0.05. All other variables were not significantly different between the groups.